Transgenic Mice Overexpressing Nuclear SREBP-1c in Pancreatic β-Cells

Akimitsu Takahashi,1 Kaori Motomura,1 Toyonori Kato,1 Tomohiro Yoshikawa,1 Yoshimi Nakagawa,1,2 Naoya Yahagi,2 Hirohito Sone,1 Hiroaki Suzuki,1 Hideo Toyoshima,1 Nobuhiro Yamada,1 and Hitoshi Shimano1,2

Influx of excess fatty acids and the resultant accumulation of intracellular triglycerides are linked to impaired insulin secretion and action in the pathogenesis of type 2 diabetes. Sterol regulatory element–binding protein (SREBP)-1c is a transcription factor that controls cellular synthesis of fatty acids and triglycerides. SREBP-1c is highly expressed in high-energy and insulin-resistant states. To investigate effects of this synthetic lipid regulator on insulin secretion, we generated transgenic mice overexpressing nuclear SREBP-1c under the insulin promoter. β-Cell–specific expression of SREBP-1c caused reduction in islet mass and impaired glucose-stimulated insulin secretion and was associated with accumulation of triglycerides, suppression of pancreatic duodenal homeobox-1, and upregulation of uncoupling protein 2 gene expression. The mice presented with impaired glucose tolerance that was exacerbated by a high-energy diet. Taken together with enhanced insulin secretion from SREBP-1–null islets, these data suggest that SREBP-1c and endogenous lipogenesis could be involved in β-cell dysfunction and diabetes. Diabetes 54:492–499, 2005

The main pathophysiological features of type 2 diabetes are defects in insulin secretion and action. The involvement of lipid accumulation in nonadipose tissue has been implicated in both pathologies, which is often referred to as “lipotoxicity,” although the molecular mechanism remains to be fully understood (1,2). Together with insulin resistance in insulin-sensitive peripheral tissues, the lipotoxicity in β-cells leading to impaired insulin secretion is also thought to precipitate the development of type 2 diabetes. β-Cell lipotoxicity has been extensively explored in association with high-plasma free fatty acids (FFAs) often observed in obesity. In vitro, long-term exposure of β-cells to FFAs results in elevated basal insulin secretion with a concomitant suppression of glucose-stimulated insulin secretion (GSIS), elevated production of reactive oxygen species, inhibition of insulin biosynthesis, and potential induction of β-cell death both in vivo and in vitro (1,3,4). Similar changes associated with the impairment of β-cell function were observed in the Zucker diabetic fatty rat (5). Long-term exposure to fatty acids could also affect the coupling of glucose metabolism to insulin secretion. Uncoupling protein (UCP)-2 has been implicated as a causative factor in this process by dissociating glucose consumption and mitochondrial ATP production, resulting in a reduction of insulin release (6,7).

Sterol regulatory element–binding protein (SREBP)-1c is a member of the SREBP family, which has been established to possess transcription factors regulating transcription of genes involved in cholesterol and fatty acid synthesis (rev. in 8). Three isoforms of SREBP, SREBP-1a, -1c, and -2, are known. Whereas SREBP-2 plays a crucial role in the regulation of cholesterol synthesis, SREBP-1c controls gene expression of lipogenic enzymes (rev. in 9–11). In vivo studies demonstrated that SREBP-1 plays a crucial role in the dietary regulation of most hepatic lipogenic genes (12,13) and that SREBP-1c expression itself is nutritionally regulated (12,14–19).

In addition to plasma fatty acid levels, factors modifying cellular fatty acid metabolism, such as hormone-sensitive lipase, have been shown to affect insulin secretion in β-cells in vivo (20). However, β-cell lipotoxicity has never been tested in terms of endogenous fatty acid synthesis. In the current study, effects of overproduction of the active form of SREBP-1c were estimated in transgenic mice to investigate potential roles of endogenous lipogenesis in pancreatic β-cell function.

RESEARCH DESIGN AND METHODS

The techniques used for generating transgenic mice were previously described (21). An expression plasmid–based vector containing a cDNA encoding nuclear human SREBP-1c (amino acids 1–436) (22), which is the constitutively active form under control of the rat insulin 1 promoter (RIP, bp –715 to 31), followed by a 3′ polyadenylation signal from the human growth hormone (hGH) cDNA, was constructed and designated pRIP-SREBP1c436. The Nofl/XhoI fragment (Fig. 1A) of pRIP-SREBP1c436 was microinjected into C57BL/6 J × SJL hybrid eggs. Founder mice were subjected to pancreactectomy and truncated human SREBP-1, as determined by RT-PCR, and two lines of

From the 1Department of Internal Medicine (Metabolism and Endocrinology), Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tennodai, Tsukuba, Ibaraki, Japan; and the 2Center for Tsukuba Advanced Research Alliance, University of Tsukuba, Tennodai, Tsukuba, Ibaraki, Japan. Address correspondence and reprint requests to Hitoshi Shimano, MD, PhD, Department of Internal Medicine, Institute of Clinical Medicine and Center for Tsukuba Advanced Research Alliance, University of Tsukuba, Tennodai, Tsukuba, Ibaraki 305-8575, Japan. E-mail: shimano-tky@umin.ac.jp. Received for publication 3 June 2004 and accepted in revised form 11 November 2004.

A.T., K.M., and T.K. contributed equally to this work.

CPT, carnitine palmitoyltransferase; FAS, fatty acid synthase; FFA, free fatty acid; GSIS, glucose-stimulated insulin secretion; HFBH, high fat/high sucrose; IGT, impaired glucose tolerance; IRS, insulin receptor substrate; KRBH, Krebs-Ringer bicarbonate buffer with 10 mmol/l HEPES; Nkx6.1, NK6 transcription factor related, locus 1; Pdx, pancreas duodenal homeobox; RIP, rat insulin 1 promoter; SCD, stearoyl CoA desaturase; SREBP, sterol regulatory element–binding protein; UCP, uncoupling protein.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
GGT-3/H11032 and 5/H11032 regular RPMI-1640 medium supplemented with 10% FCS.

CoA desaturase (SCD)-1, carnitine palmitoyltransferase (CPT)-I, UCP-2, pan-

quantitative PCR (50°C for 2 min and 95°C for 10 min, followed by 40 cycles fluorescent detection PCR or TaqMan (Applied Biosystems, Foster City, CA) (Amersham Biosciences).

yses were performed with the indicated cDNA probes using Rapid-hyb buffer performed according to the manufacturer's instructions. Northern blot anal-
treatment using the RNeasy Micro kit (Qiagen, Hilden, Germany) were
extraction with the TRIzol reagent (Invitrogen, Carlsbad, CA) and DNase-I

means

Right panel: Islets from wild type (WT) and high-expression line (line H).

panel: Islets from C57Bl6 mice incubated in the presence (PA) or the absence (Cont) of palmitate (200 μmol/l) for 48 h. All values are means ± SE.

SREBP-1c transgenic mice under the control of rat insulin promoter (TgRIP-SREBP1c) were established. SREBP-1 knockout mice used for islet investigations were as described (23).

The mice were fed a normal rodent diet (MF; Oriental yeast, Tokyo, Japan) or a synthetic high-fat/high-sucrose diet (CHS) containing 50% (wt/wt) fat and 20% (wt/wt) sucrose (24) and were housed in colony cages and main-
tained on a 12-h light/12-h dark cycle. The Animal Care Committee of the University of Tsukuba approved animal care and procedure.

Intravenous glucose tolerance tests. Glucose (1 g/kg body wt) was administered intravenously through tail vein after an overnight (12-h) fast. Blood samples were obtained from the retro-orbital plexus before (0 min) and 5, 15, and 30 min after glucose injection for plasma preparation by centrifugation.

Isolation of mouse pancreatic islets. After sacrifice by cervical dislocation, pancreatic islets were isolated by collagenase digestion of the total pancreas 30 min after glucose injection for plasma preparation by centrifugation.

Intravenous glucose tolerance tests. Glucose (1 g/kg body wt) was administered intravenously through tail vein after an overnight (12-h) fast. Blood samples were obtained from the retro-orbital plexus before (0 min) and 5, 15, and 30 min after glucose injection for plasma preparation by centrifugation.

Glucose oxidation and glucose incorporation into lipids in islets. Glucose oxidation was determined as production of 14CO2 after incubation of the islets with [U-14C]glucose (20). After terminating the glucose oxidizing reaction, inactivated islets were washed with PBS and then the tissues were extracted by islets from Folch's method and the radioactivity was counted.

The size of pancreatic islets from transgenic mice and controls. The freshly isolated pancreatic islets were visualized under a light microscope at 40X magnification using a charge-coupled device camera (CoolSnap, Roper Scientific, Trenton, NJ). The areas of islets (n = 100 from each group) were measured by numbers of pixels using the Adobe Photoshop software package (Adobe Systems, San José, CA). The islet volume was estimated as a mean of 40

Preparation of islet RNA and estimation of gene expression. Total RNA extraction with the TRIzol reagent (Invitrogen, Carlsbad, CA) and DNase-I treatment using the RNeasy Micro kit (Qiagen, Hilden, Germany) were performed according to the manufacturer's instructions. Northern blot analyses were performed with the indicated cDNA probes using Rapid-hyb buffer (Amersham Biosciences).

cDNA was synthesized with ThermoScript (Invitrogen) and real-time fluorescence detection PCR or TaqMan (Applied Biosystems, Foster City, CA) quantitative PCR (50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min) was performed with the ABI Prism 7000 PCR instrument (Applied Biosystems) to amplify the samples for human SREBP-1c (transgene), mouse SREBP-1c, fatty acid synthase (FAS), stearyl CoA desaturase (SCD-1), carnitine palmitoyltransferase (CPT-I), UCP-2, pancreas duodenal homeobox (Pdx)-1, NK6 transcription factor related, locus 1 (Nkx6.1), and cyclin-dependent kinase inhibitors. Primers and probes were as follows: 5'-GGTGGACTGGCAGAACCATC-3' and 5'-GACGGGTGTATTGACACGTG-3' with fluorescent detection for human SREBP-1c, 5'-CGCGCGGAGAAGGTTG-3' and 5'-GGTTAGCTGGGATGG-3' with antisense probe for mouse SREBP-1c, 5'-CGCGCGGAGAAGGTTG-3' and 5'-GGTTAGCTGGGATGG-3' with sense probe for mouse SREBP-1c, 5'-AGTGGTGGCAGAACCATC-3' and 5'-GACGGGTGTATTGACACGTG-3'.

RESULTS

Transgene expression in islets of TgRIP-SREBP1c mice. Two transgene-expressing lines have been established following microinjection of the construct, as depicted in Fig. 1A, to create pancreatic β-cell-specific transgenic mice overexpressing nuclear human SREBP-1c under the control of RIP. These were designated as TgRIP-SREBP1c. The higher expresser (line H) exhibited

FIG. 1. Specific overexpression of human SREBP-1c in pancreatic β-cells. A: A DNA construct for microinjection to generate transgenic mice for an active (nuclear) form of human SREBP-1c (nuc-hSREBP-1c, cDNA encoding amino acids 1–436) in pancreatic β-cells. The hybrid-
adenovirus-immunoglobulin intron (Intron) and 3′ poly A signal from the human growth hormone (hGH poly-A tail) were used. Z: Expression of transgene (hSREBP-1) and insulin in islets from a high-expression line (line H) and a low-expression line (line L) of transgenic mice and wild-type (WT) controls, as estimated by Northern blot analysis. Loading controls were by 18S ribosomal RNA. C: hSREBP-1c mRNA levels in islets from the two transgenic lines and controls by real-time quantitative PCR. mRNA levels of cyclin B1 were measured as an internal control. D: Nuclear SREBP-1c protein was detected in whole-
cell extracts of islets by immunoblotting using SREBP-1 antibody. Left panel: Islets from wild type (WT) and high-expression line (line H). Right panel: Islets from C57Bl6 mice incubated in the presence (PA) or the absence (Cont) of palmitate (200 μmol/l) for 48 h. All values are means ± SE.
detectable transgene mRNA levels by Northern blot analysis of isolated islets and was roughly seven times higher than that in low expressers (line L), as estimated by RT-PCR (Fig. 1A). Insulin gene expression was similar among these transgenic and nontransgenic littermate control mice (Fig. 1B), suggesting that use of RIP did not markedly compromise functions of mouse endogenous insulin promoters. The human SREBP-1c protein from the transgene was highly induced in islets of line H of TgRIP-SREBP1c at the level comparable to that of endogenous SREBP-1c induced by incubation with a saturated fatty acid (Fig. 1D).

**Impaired glucose tolerance in TgRIP-SREBP1c mice.**

When transgenic mice were fed a normal diet, they exhibited impaired glucose tolerance (IGT). Line H showed a slightly higher plasma glucose level at fasting, followed by significantly higher elevations after intravenous glucose loading compared with wild-type controls (Fig. 2A). A rapid increment in plasma insulin levels observed in wild type after glucose injection was markedly impaired in high expressers of TgRIP-SREBP1c, indicating impaired insulin secretion (Fig. 2B). Glucose tolerance testing in the lower expression line (line L) revealed lower insulin levels only at 5 min, with no significant difference in plasma glucose levels at other time points from littermate controls. This impairment in the early response of insulin secretion to glucose in the lower line mimics the oral glucose tolerance test pattern observed in patients with IGT or those at an early stage of type 2 diabetes. These data demonstrate that SREBP-1c overexpression in β-cells causes IGT in a dose-dependent manner. These transgenic mice did not show any difference in body weights and plasma cholesterol, triglycerides, and FFAs levels from control mice (data not shown). Insulin tolerance tests showed no significant difference between line H mice and wild-type littermates, indicating no signs of peripheral insulin resistance in the transgenic mice (Fig. 2E).

**Reduction in the number and size of islets from TgRIP-SREBP1c mouse.**

In isolation of islets from whole pancreas, the numbers of islets from TgRIP-SREBP1c were significantly decreased compared with control animals (Fig. 3A). In addition, islets from line H were considerably smaller than controls, even when taking into account intrinsic variability in islet sizes. Microscopic examination of isolated islets indicated that volume of islets was also significantly lower in transgenic animals (Fig. 3B). The reduction of islet mass was related to the levels of transgene expression and could partially explain the impaired insulin response to glucose that was observed in vivo. We also compared the size of islets from SREBP-1–null mice and did not observe a significant difference from that of wild-type mice. Insulin staining of microscopic sections demonstrated that line H showed a similar pattern to that of wild type, indicating that there was not a marked reduction in the number of β-cells per islet, although there was a slight decrease in intensity of insulin immunoreactivity (Fig. 3C).

**Disturbed GSIS from isolated islets of TgRIP-SREBP1c mouse.**

Insulin secretion was estimated from isolated islets of similar sizes. Basal insulin secretion in low-glucose medium (2.8 mmol/l) was slightly decreased in line L, but not in line H, as compared with wild-type islets. GSIS in high-glucose medium (20 mmol/l) was significantly impaired in both line H and L (Fig. 3D). Conversely, islets from SREBP-1c–null mice showed a trend to a higher insulin secretion in glucose response. In contrast to reduced GSIS, insulin secretion stimulated by KCl was not impaired in islets from TgRIP-SREBP1c. Insulin content was decreased in islets from TgRIP-SREBP1c, which also partially explains the GSIS suppression (Fig. 3E). Consistent with disturbances in GSIS, ATP content was decreased in SREBP-1c–expressing β-cells (Fig. 3F). The glucose oxidation in islets from TgRIP-SREBP1c was also reduced, supporting the impaired ATP
Reflecting forced expression of human nuclear SREBP-1c in \( \text{H9252} \)-cells, contents of triglycerides from pancreatic islets, corrected for by relative islet volume, were increased in TgRIP-SREBP1c in a transgene expression–dependent manner (Fig. 3H). In contrast, islets from SREBP-1–null mice contained markedly less triglycerides than those from wild type. Glucose incorporation into lipid was increased in the islets from TgRIP-SREBP1c mice (Fig. 3I). These data suggest that SREBP-1c could regulate islet triglyceride content through regulation of endogenous synthesis and play a negative role in GSIS in \( \text{H9252} \)-cells. The disturbance was located prior the ATP-sensitive K\(^+\) channel level.

UCP-2 is upregulated and Pdx-1 is downregulated in SREBP-1c–overexpressing islets. Expression of various genes in islets was estimated by RT-PCR to elucidate the molecular mechanism for insulin secretion disturbance in TgRIP-SREBP1c (Fig. 4). The endogenous mouse SREBP-1c mRNA level did not show significant changes in wild type and the two transgenic lines. Consistent with increased triglyceride contents, mRNA levels of FAS and SCD-1, key enzymes for synthesis of fatty acids and major transcriptional target genes of SREBP-1c, were also markedly elevated in TgRIP-SREBP1c islets in a transgene expression–dependent manner. UCP-2, recently established as a regulator for ATP production and a marker for mitochondrial stress, has been reported to negatively regulate insulin secretion in \( \text{H9252} \)-cells (6,27). Gene expression of UCP-2 was dose dependently upregulated by SREBP-1c overexpression, explaining ATP depletion in TgRIP-SREBP1c islets. It was also found that Pdx-1, a homeodomain product that plays an important role in pancreatic islet genesis and insulin gene regulation (28 –30), was dose dependently downregulated by SREBP-1c. Conversely, these genes are regulated in opposite directions by SREBP-1c depletion. Expression of IRS-2, an important insulin signaling mediator, was sup-
pressed in TgRIP-SREBP-1c islets, consistent with our previous observation in livers (32).

**Suppression of hyperinsulinemia and exacerbated IGT in TgRIP-SREBP1c mice by a high-energy diet.** To overload requirement for insulin secretion, TgRIP-SREBP1c mice were put on a HFHS diet. This high-energy diet induced an insulin-resistant state with obesity and hyperinsulinemia, as evidenced by gradual increases in body weight, fasting plasma glucose, and insulin levels in wild-type mice (Fig. 5A, B, and C). Whereas line H of TgRIP-SREBP1c mice also exhibited a similar time course change in body weight, hyperinsulinemia was markedly suppressed, highlighting an insulin secretion defect in these mice. An intravenous glucose tolerance test was performed at 16 weeks after the HFHS diet, at the time point when increased blood glucose level was significant. TgRIP-SREBP1c became more diabetic, showing evidently higher plasma glucose levels than wild type (Fig. 6A). In the transgenic mice on HFHS diet, plasma insulin levels did not respond to glucose loading and instead were decreased (Fig. 6B). Consistent with exacerbation in IGT, islets from the transgenic mice on a high-fat diet essentially lost glucose response to insulin secretion, whereas in normal mice, insulin secretion on HFHS diet was enhanced (Fig. 6C). Triglyceride contents in islets were increased in both wild type and TgRIP-SREBP1c by HFHS diet, and the difference was still appreciable (Fig. 6D). HFHS-induced obesity and insulin resistance was followed by hyperinsulinemia from enlarged islets in wild-type mice (Fig. 6E). Consistent with insulin secretion defect, this islet enlargement was markedly suppressed in TgRIP-SREBP1c on HFHS diet. The number and size of islets were appreciably reduced on hematoxylin-eosin staining of microscopic examination (Fig. 6E and F), implicating that SREBP-1c could play a negative role in β-cell growth.

**DISCUSSION**

Current studies clearly demonstrate that activation of SREBP-1c in β-cells caused the onset of IGT or mild diabetes due to impaired insulin secretion. Reduction in β-cell mass, indicated by decreases in both the number and size of TgRIP-SREBP1c islets, at least partially contributes to these phenotypes. Retarded growth of islets by SREBP-1c was more obvious with marked impairment in insulin response to glucose when the high-energy diet evoked obesity-induced peripheral insulin resistance, enhancing insulin requirement for these mice. Meanwhile, in comparison with islets of similar size, GSIS from TgRIP-SREBP1c was significantly decreased compared with that from control mice. Suppression of GSIS by SREBP-1c is consistent with previous data on β-cell lines (33). Thus, impaired insulin secretion of TgRIP-SREBP-1c in vivo is featured by two abnormalities: islet volume loss and dysfunction of β-cells.

The amount of SREBP-1c expression was positively associated with triglyceride content of islets and negatively with GSIS in a wide range from SREBP-1c–null mice to high expressers. As established in livers and adipose tissue, SREBP-1c activates expression of lipogenic genes, such as FAS and SCD-1 in β-cells, whereas expression of...
CPT-I and PPARα was slightly increased (Fig. 4 and data not shown), suggesting that triglyceride accumulation in β-cells from TgRIP-SREBP1c is due to enhanced synthesis rather than decreased degradation of fatty acids. Moreover, the glucose incorporation into lipid was accelerated in islets from TgRIP-SREBP1c. These data suggest that SREBP-1c led to impaired insulin secretion through lipotoxicity by activation of fatty acid and triglyceride synthesis. Lipotoxicity in β-cells was originally proposed to be a result of influx of high-plasma fatty acids often associated with obesity. TgRIP-SREBP1c mice were not obese, and plasma FFA levels were not elevated. Thus, these mice provide a new model for β-cell lipotoxicity, the etiology of which is extended to increased endogenous lipogenesis. Accelerated lipogenesis by SREBP-1c is associated with consumption of acetyl-CoA and glucose, which could lead to diminished ATP production.

UCP-2 upregulation in TgRIP-SREBP1c islets could play an important role in molecular mechanisms, by which SREBP-1c causes β-cell dysfunction, as already noticed in cultured cells (34–36). It has been recently demonstrated that UCP-2 negatively regulates insulin secretion (6,27). Activation of UCP-2 by fatty acids was suggested to play an important role in obesity-induced β-cell dysfunction induced by exogenous fatty acid or triglyceride loading as the inducer of lipotoxicity (20,27). In addition to fatty acid–mediated induction, SREBP was reported to directly modulate transcription of key genes such as Pdx-1 and UCP-2, which could provide a new role for SREBP-1c in β-cells. In addition, we recently reported that SREBP-1c suppresses insulin signaling in liver by repression of IRS-2 gene expression (32). Suppression of IRS-2 expression was also observed in TgRIP-SREBP1c islets, which could lead to impaired insulin secretion, as already suggested in β-cell–specific insulin receptor knockout or IRS-2 knockout mice (33,40).

The potential for endogenous SREBP-1c to be involved in the pathophysiology of β-cells is highly relevant and needs to be studied to verify the significance in the current data of our ectopic expression experiments. In several insulin-resistant animals, such as Zucker fatty rats and ob/ob mice, SREBP-1c is highly expressed in both liver and islets (41). Also, it has been reported that endogenous nuclear SREBP-1c was upregulated by exposure to a high-glucose medium in hepatocytes and β-cell lines (19,42). Hyperglycemia, as observed in STZ-induced diabetic, insulin-depleted mice, could stimulate SREBP-1c expression in the liver (26). β-Cells and hepatocytes take up glucose through insulin-independent GLUT2, which prompts us to speculate that endogenous SREBP-1c in β-cells could be activated and involved in glucolipotoxicity in diabetic states with severe hyperglycemia. An opposite phenotype in islets of SREBP-1 knockout mice compared with TgRIP-SREBP1c islets strongly supports the involvement of SREBP-1c in β-cell lipotoxicity. Thus, these mice are not only a good model for IGT and type 2 diabetes but...
also a useful tool to investigate a novel mechanism of insulin secretion defects. Further studies are needed to investigate the more precise molecular mechanism by which SREBP-1c could cause β-cell dysfunction and growth impairment and to seek potential roles for SREBP-1c in clinical relevance to some clinical categories of type 2 diabetes, such as nonobese Japanese patients (43).

ACKNOWLEDGMENTS

This work was supported by grants-in-aid from the Ministry of Science, Education, Culture, and Technology of Japan. The authors are grateful to Dr. A.H. Hasty for critical reading of this manuscript and to Drs. S. Ishibashi and J. Osuga for helpful discussion.

REFERENCES

29. Ohlson H, Karlsson K, Edlund T, IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 12:4251–4259, 1993


40. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904, 1998

